Sintx Technologies, Inc.
SINTNasdaqHealthcare · Surgical & Medical Instruments & Apparatus · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $1.0M | $2.9M | $2.6M | $1.6M | $606,000 | $594,000 |
| Operating income | −$10.7M | −$14.0M | −$13.4M | −$11.3M | −$10.6M | −$8.5M |
| Net income | −$10.4M | −$11.0M | −$8.3M | −$12.0M | −$9.3M | −$7.0M |
| Total assets | $9.5M | $9.4M | $15.4M | $15.8M | $21.8M | $30.4M |
| Total liabilities | $6.6M | $5.5M | $6.6M | $10.1M | $4.6M | $4.6M |
| Equity | $2.9M | $3.9M | $8.8M | $5.7M | $17.2M | $25.8M |
| EPS (diluted) | $-6.16 | $-15.19 | $-624.47 | $-60.81 | $-39.91 | $-1.08 |
| Shares out. | 2.5M | 22.7M | 3.9M | 24.7M | 24.7M | 10.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −1053.1%
- Net margin
- −1018.1%
- Return on equity
- −353.8%
- Return on assets
- −109.0%
- Return on capital (ROCE)
- −185.7%
- Liabilities / assets
- 69.2%
- Debt / equity
- 2.25×
- Book value / share
- $1.16
- Revenue growth (YoY)
- −64.7%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -105.96distress
- Accruals / assets
- −18.9%clean
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 4 warning● 1 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗May 16, 2019
- NT 10-Qmissed a reporting deadline ↗Aug 16, 2017
- NT 10-Qmissed a reporting deadline ↗May 16, 2017
- NT 10-Kmissed a reporting deadline ↗Mar 31, 2017
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Honigblum Gregg R.Passive (13G)Dec 9, 2025
- Virtus Wealth Solutions LlcPassive (13G)Nov 14, 2025
- Sinaptic Holdings, LlcPassive (13G)Nov 14, 2025
- Murphy Kevin PPassive (13G)Sep 3, 2025
- Lind Global Fund Ii LpPassive (13G)May 15, 2025
- Medtech Ceramics, LpPassive (13G)Mar 25, 2025
- L1 Capital Global Opportunities Master Fund, Ltd.Passive (13G)Feb 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Elmore Robert RyanOfficer — President | Apr 13, 2026 | Grant | 4,910 | $2.88 |
| Lyons Christopher MichaelDirector | Feb 25, 2026 | Buy | 758 | $2.96 |
| Moyes Jay MDirector | Feb 23, 2026 | Buy | 1,000 | $2.91 |
| Anderson Mark LewisDirector | Feb 18, 2026 | Buy | 3,000 | $3.02 |
| Honigblum Gregg R.Officer — Chief Investment Officer | Dec 8, 2025 | Buy | 3,200 | $4.28 |
| Honigblum Gregg R.Officer — Chief Investment Officer | Nov 7, 2025 | Buy | 5,000 | $3.20 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 210,650 | 4.8 | -5.3% |
| Apr 30, 2026 | 222,373 | 6.4 | +11.2% |
| Apr 15, 2026 | 199,913 | 6.5 | -21.8% |
| Mar 31, 2026 | 255,636 | 7.5 | +20.6% |
| Mar 13, 2026 | 211,999 | 6.7 | -5.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Delisting / listing-standard noticeMay 27, 2026
- Director / officer changeFeb 18, 2026
- Regulation FD disclosureDec 1, 2025
- Results of operations · Regulation FD disclosureNov 13, 2025
- Entered a material agreementOct 3, 2025
- Entered a material agreement · Unregistered equity saleSep 9, 2025
- Director / officer change · Shareholder voteSep 5, 2025
- Regulation FD disclosureJul 22, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.